It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Survey data from the Mayo Clinic Breast Disease Registry were used to assess fertility counseling and fertility preservation strategies in a modern cohort of young women with breast cancer. One hundred respondents were identified who were under age 50 at the time of breast cancer diagnosis and who expressed interest in future childbearing near the time of diagnosis and/or 1 year later. Ninety-three percent of the 81 respondents to the year one survey recalled fertility counseling prior to cancer treatment. Most who reported a high level of fertility concern declared that this concern had impacted their treatment decisions, often shortening their planned duration of endocrine therapy. Approximately half had taken steps to preserve future fertility, and a third had used a gonadotropin-releasing hormone agonist either alone or combined with another method (e.g., embryo or oocyte cryopreservation).
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details













1 Mayo Clinic, Department of Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
2 Mayo Clinic, Department of Oncology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
3 Mayo Clinic, Department of Obstetrics and Gynecology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
4 University of North Carolina, Department of Epidemiology, Chapel Hill, USA (GRID:grid.10698.36) (ISNI:0000 0001 2248 3208)
5 University of California San Diego, Department of Obstetrics and Gynecology, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
6 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
7 Mayo Clinic, Mayo Clinic Comprehensive Cancer Center, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
8 Mayo Clinic, Department of Quantitative Health Sciences, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)